CNO Financial Group, Inc. (CNO): what the price requires

At today's price, CNO Financial Group, Inc. (CNO) is priced for 16.4% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/CNO

Headline

FieldValue
TickerCNO
CompanyCNO Financial Group, Inc.
Current price$52.28/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed16.4%
Return on equity now8.7%
ROE gap+7.7pp
Price-to-book1.95x

Solve inputs: computed at a 10.3% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~2pp.

Reconcile: at the x-ray's 9.3% required return this reads ~14.3%; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history+1.71σ
cohort percentile (of 80 peers)54
sustained it ~10 years at this level56%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.84x3expensive
Earnings1.30x2expensive
Relative0.60x3justifies
Growth1.01x1expensive

Families that justify the price: Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 1.9%); the inversion above states its own rate.

Per-Model Detail (n=9)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$25.992.01xyesTBVPS $25.99 × 1.00x (ROE (TTM) 9.8% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 0.51% allowance/loans → ×0.88)
Relative ValuationRelative$37.091.41xyesP/E 13.84x (blended: static sector reference 11x + trailing (TTM) 20x), scenarios: 11.6x / 13.8x / 16.0x (bear / base = reference held flat / bull), EV/EBITDA 19.19x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$27.611.89xyesBV/sh $25.99, ROE (TTM) 9.8%, ke 9.3%
Two-Stage Excess ReturnAsset$28.431.84xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$51.531.01xyesRev $4.5B, growth 5% (input: historical growth; tapered), Terminal P/S: 0.9x / 1.1x / 1.3x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$87.150.60xyesEPS $2.49, growth 35% (input: historical EPS growth), PEG=0.58 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$38.161.37xyes√(22.5 × EPS $2.49 × BVPS $25.99) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$80.340.65xyesEPS $2.49 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$93.370.56xyesEPS $2.49 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$26.921.94xyesEPS $2.49 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (buyback)-5.6%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

CNO is an insurer, so the price is best read against book value and the returns earned on it. At $50.88 the stock trades near 2x book of about $26 per share on a return on equity running near 10%, which is a premium the business has to keep earning rather than one already banked.

The recent operating momentum is real: first-quarter 2026 operating EPS rose 33% to $1.05, the fifteenth straight quarter of sales growth, with Medicare and supplemental health doing the heavy lifting and management guiding full-year operating EPS to $4.25 to $4.45.

The balance sheet is an insurer's balance sheet, not a leverage story: about $38.8 billion of total assets against $2.6 billion of equity, with a commercial mortgage book near $1.8 billion and a long-term-care reserve that depends on rate increases regulators have to approve. The buyback is steady, with shares shrinking about 5.6% a year.

Bull Case

Insurers are hard to value because the product is a promise priced today and paid out over decades, so the honest anchor is book value and the return earned on it, not a revenue multiple. CNO reports $38.8 billion of total assets against $2.6 billion of shareholders' equity (FY2025 10-K, accession 0001224608-26-000017), book value near $26 per share, and a return on equity running close to 10%. The bull case is that this return is climbing and management has a credible plan to lift it further. Full-year 2026 guidance targets operating EPS of $4.25 to $4.45 and a run-rate operating return-on-equity improvement of about 200 basis points through 2027, and the first-quarter print backed it up with operating EPS up 33% to $1.05.

The distribution is the moat. CNO sells health, annuity, and individual life through exclusive agents, independent producers, and direct marketing into what it describes as attractive, underserved, high-growth middle-income markets (FY2025 10-K, accession 0001224608-26-000017). That exclusive-agent channel is hard to replicate and well suited to the supplemental-health and Medicare products that are growing fastest: the company posted its thirteenth consecutive quarter of producing-agent-count growth, with total Medicare policies sold up 24% and Medicare Supplement new annualized premium up 53% in the quarter. On the spread side, fixed indexed annuity premium collections rose 12.8% to about $1.74 billion in 2025 (accession 0001224608-26-000017), so the savings franchise is feeding the balance sheet at the same time the protection franchise grows.

The capital return turns a single-digit return on equity into double-digit per-share progress. CNO repurchased $60 million of stock in the quarter and returned $77 million to shareholders in total, the board authorized a fresh buyback, and shares outstanding have been shrinking roughly 5.6% a year. The dividend was raised. Across the model lenses, the relative-valuation read at a sector-median P/E near 17x lands close to the current price, and the earnings-growth and PEG-based methods, working off about $2.49 of trailing EPS, land well above it. For an insurer compounding book value, buying back stock, and lifting return on equity, paying around 2x book is a bet that the ROE-improvement plan and the Medicare tailwind hold, and the recent results say both are tracking.

Bear Case

The first thing chipping at the case is the durability of the spread itself. CNO is, underneath the growth headlines, an old-line life-and-health insurer whose economics rest on earning more on its investments than it credits to policyholders and reserves. It holds commercial mortgage loans of about $1.8 billion, roughly 6% of invested assets, plus a residential mortgage book (FY2025 10-K, accession 0001224608-26-000017), and it manages the relationship between asset and liability durations precisely because a mismatch shows up directly in the value of the franchise (accession 0001224608-26-000017). A return on equity near 10% against a cost of equity around 9% is a thin excess return; the asset-based valuation lenses, which value the business on book value plus the present value of returns earned above that cost, land in the high $20s, well below the $50.88 price (June 27, 2026). In other words, the methods grounded in the actual book of business say the premium to book is doing most of the work.

Long-term care is the legacy block that keeps the moat from being clean. CNO writes long-term-care business whose economics depend on actuarially justified rate increases it must file for and regulators must approve (FY2025 10-K, accession 0001224608-26-000017). That is an advantage that erodes if regulators slow-walk increases or claims experience worsens, and it is the kind of long-tail liability that has surprised the whole industry before. The reserve sits inside a present-value framework that flexes with discount-rate assumptions (accession 0001224608-26-000017), so a change in the rate environment can move the liability independently of how the business is selling.

The valuation leaves little room for the spread to compress. At about 2x book, the price already embeds the return-on-equity improvement plan succeeding; if rates fall and reinvestment yields drop, or if the long-term-care block requires reserve strengthening, the same multiple that flatters the stock on the way up reverses. It is worth noting the gap between the model and the analyst view: sell-side price targets cited around the upgrade clustered near $28 to $32, which is below the current price and closer to where the book-value and excess-return methods land than to where the stock trades. A buyer here is paying for growth and capital return to keep outrunning a structurally modest underlying return on equity.

Valuation

For a financial, the cleanest lens is book value and the return on it rather than a cash-flow DCF, and the methods sort accordingly. Book value sits near $26 per share with return on equity around 10% and a cost of equity near 9%, so the excess-return and residual-income methods, which capitalize the thin spread of ROE over the cost of equity onto book, land in the high $20s. The relative-valuation read, pricing the stock at a sector-median P/E near 17x off about $2.49 of trailing EPS, lands near $46, close to the current price. The growth-leaning methods that extrapolate recent EPS growth, such as the PEG and Peter Lynch reads, land far higher, in the $80s to $90s, which is exactly the disagreement to weigh: the asset lenses say the franchise is worth its book plus a modest premium, while the growth lenses say recent momentum justifies far more.

Reading the price as an implied assumption, at $50.88 the market is paying roughly 2x book for a business earning about 10% on equity, which is a premium that only makes sense if return on equity rises toward the 200-basis-point improvement management is guiding to. A reverse band built on the financials basis spans about $5 at the bear end, $15 at the base, and $27 at the bull end, reflecting how sensitive an insurer's intrinsic value is to the spread and reserve assumptions; the current price sits above that band, so the market is underwriting the optimistic end of the ROE path. Note that a handful of the X-ray methods that assume an industrial cash-flow or EV/EBITDA structure are not meaningful for an insurer and have been set aside; the book-value, relative, and earnings-based reads carry the weight here.

Catalysts

First-quarter 2026 was the recent set-piece and it was strong: operating EPS rose 33% to $1.05, beating estimates by about 12%, on revenue of roughly $1.03 billion. Management called it the fifteenth consecutive quarter of sales growth and the thirteenth of producing-agent-count growth, with total Medicare policies sold up 24% and Medicare Supplement new annualized premium up 53%. (Sources: CNO Financial Q1 2026 earnings call highlights and summary via Yahoo Finance; MarketBeat Q1 2026 earnings report.)

Management reaffirmed full-year 2026 guidance of $4.25 to $4.45 operating EPS, an 18.8% to 19.2% expense ratio, $200 to $250 million of free cash flow, and a plan to lift run-rate operating return on equity by about 200 basis points through 2027. The next read is the Q2 print, where the watch items are whether agent count and Medicare sales keep compounding and whether the investment spread holds if rates move.

On capital return, CNO repurchased $60 million of shares in the quarter, returned $77 million to shareholders in total, raised the dividend, and the board approved a further buyback, continuing the roughly 5.6% annual reduction in share count. On sentiment, JMP Securities upgraded the stock to Market Outperform citing favorable insurance conditions and improved catastrophe-loss trends, with cited analyst price targets clustering around $28 to $32. (Sources: AInvest coverage of the CNO upgrade ahead of Q1; CNO dividend history via StockAnalysis; Yahoo Finance dividend-raise coverage.)

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive CNO report on boothcheck